Amicus Therapeutics (FOLD) Short Interest Ratio & Short Volume → How Biden has already won 2024 (From Porter & Company) (Ad) Free FOLD Stock Alerts $9.57 +0.07 (+0.74%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics Short Interest DataCurrent Short Volume28,770,000 sharesPrevious Short Volume31,320,000 sharesChange Vs. Previous Month-8.14%Dollar Volume Sold Short$287.41 millionShort Interest Ratio / Days to Cover9.4Last Record DateApril 30, 2024Outstanding Shares296,200,000 sharesPercentage of Shares Shorted9.71%Today's Trading Volume2,151,178 sharesAverage Trading Volume3,009,051 sharesToday's Volume Vs. Average71% Short Selling Amicus Therapeutics ? Sign up to receive the latest short interest report for Amicus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatFOLD Short Interest Over TimeFOLD Days to Cover Over TimeFOLD Percentage of Float Shorted Over Time Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. Amicus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202428,770,000 shares $287.41 million -8.1%N/A9.4 $9.99 4/15/202431,320,000 shares $333.87 million -3.6%N/A10.3 $10.66 3/31/202432,490,000 shares $382.73 million +0.3%N/A10.7 $11.78 3/15/202432,400,000 shares $371.95 million +4.8%N/A10.3 $11.48 2/29/202430,910,000 shares $396.27 million +15.4%N/A9.4 $12.82 2/15/202426,780,000 shares $374.92 million +9.8%N/A8.6 $14.00 Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202424,400,000 shares $303.29 million -2.6%N/A8.1 $12.43 1/15/202425,060,000 shares $330.29 million -2.7%N/A8.3 $13.18 12/31/202325,750,000 shares $365.39 million -4.3%N/A8.8 $14.19 12/15/202326,910,000 shares $342.30 million +11.5%N/A9.2 $12.72 11/30/202324,140,000 shares $266.02 million +6.2%N/A9.6 $11.02 11/15/202322,730,000 shares $242.30 million +0.8%N/A9.6 $10.66 10/31/202322,560,000 shares $247.48 million +0.4%N/A10 $10.97 10/15/202322,480,000 shares $234.69 million +19.1%N/A9.3 $10.44 9/30/202318,870,000 shares $229.46 million -0.2%N/A7.9 $12.16 9/15/202318,900,000 shares $247.40 million -3.8%N/A8.6 $13.09 8/31/202319,640,000 shares $251.78 million +3.1%N/A8.5 $12.82 8/15/202319,050,000 shares $247.46 million -16.6%N/A7.9 $12.99 7/31/202322,830,000 shares $310.94 million +13.3%N/A8.2 $13.62 7/15/202320,150,000 shares $270.01 million -6.5%N/A7.9 $13.40 6/30/202321,540,000 shares $270.54 million +10.0%N/A8.7 $12.56 6/15/202319,580,000 shares $253.76 million +2.4%N/A7.6 $12.96 5/31/202319,120,000 shares $215.29 million -10.2%N/A7.6 $11.26 5/15/202321,300,000 shares $238.56 million -1.1%N/A8.7 $11.20 4/30/202321,530,000 shares $248.46 million +2.2%N/A9.8 $11.54 4/15/202321,060,000 shares $240.08 million +5.4%N/A9.9 $11.40 3/31/202319,980,000 shares $221.58 million -4.3%N/A8.9 $11.09 3/15/202320,880,000 shares $238.66 million +15.4%N/A9.8 $11.43 2/28/202318,090,000 shares $238.61 million +0.2%N/A8.6 $13.19 2/15/202318,060,000 shares $236.77 million -8.1%N/A8.8 $13.11 1/31/202319,650,000 shares $256.24 million +1.5%N/A9.3 $13.04 1/15/202319,370,000 shares $248.52 million -3.8%N/A8.5 $12.83 12/30/202220,140,000 shares $245.91 million +12.6%N/A9.2 $12.21 12/15/202217,880,000 shares $216.17 million -12.0%N/A7.8 $12.09 11/30/202220,310,000 shares $245.75 million +7.6%N/A8.3 $12.10 11/15/202218,880,000 shares $220.33 million +3.4%N/A7.4 $11.67 10/31/202218,260,000 shares $182.60 million -12.1%N/A7.1 $10.00 10/15/202220,780,000 shares $220.27 million +2.3%N/A7.8 $10.60 9/30/202220,310,000 shares $212.04 million -8.5%N/A7.3 $10.44 9/15/202222,200,000 shares $243.09 million +2.5%N/A7.4 $10.95The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. FOLD Short Interest - Frequently Asked Questions What is Amicus Therapeutics' current short interest? Short interest is the volume of Amicus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 28,770,000 shares of FOLD short. Learn More on Amicus Therapeutics' current short interest. What is a good short interest ratio for Amicus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FOLD shares currently have a short interest ratio of 9.0. Learn More on Amicus Therapeutics's short interest ratio. Which institutional investors are shorting Amicus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Amicus Therapeutics: Walleye Trading LLC, and Torno Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Amicus Therapeutics' short interest increasing or decreasing? Amicus Therapeutics saw a drop in short interest in April. As of April 30th, there was short interest totaling 28,770,000 shares, a drop of 8.1% from the previous total of 31,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Amicus Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Amicus Therapeutics: Geron Co. (8.82%), Ligand Pharmaceuticals Incorporated (4.42%), Dynavax Technologies Co. (14.99%), Perrigo Company plc (2.54%), Alkermes plc (7.62%), MannKind Co. (13.13%), Ironwood Pharmaceuticals, Inc. (13.04%), Madrigal Pharmaceuticals, Inc. (18.67%), Innoviva, Inc. (18.39%), OPKO Health, Inc. (26.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Amicus Therapeutics stock? Short selling FOLD is an investing strategy that aims to generate trading profit from Amicus Therapeutics as its price is falling. FOLD shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Amicus Therapeutics? A short squeeze for Amicus Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FOLD, which in turn drives the price of the stock up even further. How often is Amicus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FOLD, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Geron Short Interest Ligand Pharmaceuticals Short Interest Dynavax Technologies Short Interest Perrigo Short Interest Alkermes Short Interest MannKind Short Interest Ironwood Pharmaceuticals Short Interest Madrigal Pharmaceuticals Short Interest Innoviva Short Interest OPKO Health Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FOLD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings